Listings of claims:

1-10. (Canceled)

11. (Currently Amended) A compound 2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[2-(1,3-benzodioxol-5-yl)ethyl]-(2S)-propylamine or a salt, or in-vivo hydrolyzable ester ~~pro-drug or solvate~~ thereof.

12. (Cancelled)

13. (Currently amended) A pharmaceutical formulation comprising a compound, or salt, or in-vivo hydrolyzable ester ~~pro-drug or solvate~~ thereof, according to claim 11 and a pharmaceutically acceptable diluent or carrier.

14. (Withdrawn) A method of antagonising gonadotropin releasing hormone activity in a patient, the method comprising administering a compound, or salt, pro-drug or solvate thereof, according to claim 1 to a patient.

15. (Withdrawn) A method of treating and/or preventing a sex hormone related condition in a patient, the method comprising administering a compound according to claim 1, or salt, pro-drug or solvate thereof, to a patient.

16. (Withdrawn) A process for the preparation of a compound of Formula (I) as defined in Claim 1, comprising a process selected from (a) to (h) as follows:

    (a) Reaction of a compound of formula **XXXII** with a compound of formula H-$\mathbf{R^{5}}$ to form a compound of Formula (I),



XXXII **Formula (I)**

wherein $\mathbf{X^1}$ is selected from:  and  ; $\mathbf{L^1}$ is a displaceable group; and

$\mathbf{H\text{-}R^{5'}}$ is selected from:



;

(b) Reaction of a compound of formula **XXXIII** with a compound of formula $\mathbf{H\text{-}R^{5''}}$ to form a compound of Formula (I),



XXXIII **Formula (I)**

wherein $\mathbf{X^2}$ is selected from:  ; $\mathbf{L^2}$ is a displaceable group and $\mathbf{R^{7a}}$ is selected from the definition of $\mathbf{R^7}$ or $\mathbf{R^{22}}$ above, and

L^2-$R^{5''}$ is selected from:

L^2—B—R^8 , L^2—J—K—R^8 and L^2—R^{21}

(c) For compounds of Formula (I) wherein R^3 is a group of Formula (IIa), (IIb), (IIc) or (IId) and R^7 is other than part of a heterocyclic ring or hydrogen, reaction of a compound of Formula (I) wherein R^3 is a group of Formula (IIa), (IIb), (IIc) or (IId) and R^7 is hydrogen with a group of formula L^3-R^{7a}, wherein R^{7a} is as defined above for R^7 with the exclusion of hydrogen and L^3 is a displaceable group;

(d) For compounds of Formula (I) wherein R^3 is a group of Formula (IIe) or (IIf) and R^{21} is other than hydrogen, reaction of a compound of Formula (I) wherein R^3 is a group of Formula (IIe) or (IIf) and R^{21} is hydrogen with a group of formula L^4-R^{21a}, wherein R^{21a} is as defined above for R^{21} with the exclusion of hydrogen and L^4 is a displaceable group;

(e) For compounds of Formula (I) wherein R^3 is a group of Formula (IIe) or (IIf) and R^{22} is other than hydrogen, reaction of a compound of Formula (I) wherein R^3 is a group of Formula (IIe) or (IIf) and R^{22} is hydrogen with a group of formula L^5-R^{22a}, wherein R^{22a} is as defined above for R^{22} with the exclusion of hydrogen and L^5 is a displaceable group;

(f) For compounds of Formula (I) wherein R^3 is a group of Formula (IIc) or (IId) and

the group  together forms an optionally substituted nitrogen-containing heterocyclic ring containing 4-7 carbons atoms, reaction of a compound of Formula **XXXIVa** or **XXXIVb**, with a compound of Formula L^6-K-R^8, wherein L^3 is a displaceable group



XXXIVa



XXXIVb

(g) For compounds of Formula (I) wherein R^3 is a group of Formula (IIc) or (IId), reaction of a compound of Formula **XXXVa** or **XXXVb**, with a compound of Formula L^7-K''-R^8, wherein L^7 is a displaceable group, and wherein the groups **K'** and **K''** comprise groups which when reacted together form **K**,



XXXVa



XXXVb ;

(h) reaction of a compound of Formula **XXXVI** with a compound of the formula L^8-R^5, wherein L^8 is a displaceable group

XXXVI ;

and thereafter if necessary:

i) converting a compound of the Formula (I) into another compound of the Formula (I);

ii) removing any protecting groups;

iii) forming a salt, pro-drug or solvate.

17. (Currently Amended) A compound of Formula (I),



Formula (I),

or a salt, or in-vivo hydrolyzable ester ~~pro-drug or solvate~~ thereof, wherein

$\mathbf{R^1}$ is hydrogen;

$\mathbf{R^2}$ is 3,5-dimethylphenyl;

M is $-CH_2-O-$;

$\mathbf{R^5}$ is 2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy;

$\mathbf{R^3}$ is Formula (IIb),



Formula (IIb),

wherein,

$\mathbf{R^6}$ is hydrogen;

$\mathbf{R^{6a}}$ is methyl;

$\mathbf{R^7}$ is hydrogen;

$\mathbf{R^8}$ is 1,3-benzodioxol-5-yl;

A is methylene; and

B is selected from ethylene and butylene.

18. (New) A compound of Formula (I),



Formula (I)

wherein

R^1 is selected from: hydrogen, optionally-substituted C_{1-6}alkyl, optionally substituted aryl or optionally-substituted arylC_{1-6}alkyl;

R^2 is optionally-substituted phenyl;

R^3 is selected from a group of Formula (IIa) to Formula (IIf):



Formula (IIa)



Formula (IIb)



Formula (IIc)



Formula (IId)



Formula (IIe)



Formula (IIf)

R^5 is a group of Formula (III):

Formula (III)

R^6 and R^{6a} are independently selected from hydrogen, fluoro, optionally substituted C_{1-6}alkyl or **R^6** and **R^{6a}** taken together and the carbon atom to which they are attached form a carbocyclic ring of 3-7 atoms

R^7 is selected from: hydrogen, optionally-substituted C_{1-6}alkyl, optionally-substituted arylC_{1-6}alkyl, optionally-substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylC_{1-6}alkyl, **R^9**OC_{1-6}alkyl-, **R^9R^{10}**NC_{1-6}alkyl-, **R^9R^{10}**NC(O)C_{1-6}alkyl, -C(NR^9R^{10})=NH; or when **R^3** is a group of Formula (IIc) or (IId) **R^7** is of the formula –**J**-**K**-**R^8**;

R^8 is selected from:

(i) hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, haloC_{1-6}alkyl, C_{1-4}alkoxyC_{1-4}alkyl, hydroxy, hydroxyC_{1-6}alkyl, cyano, N-C_{1-4}alkylamino, N,N-di-C_{1-4}alkylamino, C_{1-6}alkyl–S(O_n)-, -O-**R^b**, –N**R^bR^c**, –C(O)-**R^b**, –C(O)O-**R^b**, -CON**R^bR^c**, NH-C(O)-**R^b** or –S(O_n)N**R^bR^c**, where **R^b** and **R^c** are independently selected from hydrogen and C_{1-4}alkyl optionally substituted with hydroxy, amino, N-C_{1-4}alkylamino, N,N-di-C_{1-4}alkylamino, HO-C_{2-4}alkyl-NH- or HO-C_{2-4}alkyl-N(C_{1-4}alkyl)-;

(ii) nitro when **B** is a group of Formula (IV) and **X** is CH and **p** is 0;

(iii) C_{3-7}cycloalkyl, aryl or arylC_{1-6}alkyl each of which is optionally substituted by **R^{12}**, **R^{13}** and **R^{14}**;

(iv) -(**Q**)-aryl , -(**Q**)-heterocyclyl, -aryl-(**Q**)-aryl, each of which is optionally substituted by **R^{12}**, **R^{13}** and **R^{14}** wherein -(**Q**)- is selected from **E**, **F** or a direct bond;

(v) heterocyclyl or heterocyclylC_{1-6}alkyl each of which is optionally substituted by up to 4 substituents independently selected from **R^{12}**, **R^{13}** and **R^{14}**;

(vi) a group selected from **R^{12}**, **R^{13}** and **R^{14}**;

R^9 and **R^{10}** are independently selected from: hydrogen, hydroxy, optionally substituted C_{1-6}alkyl, optionally substituted aryl, optionally substituted arylC_{1-6}alkyl, an optionally substituted carbocyclic ring of 3-7 atoms,

optionally substituted heterocyclyl, optionally substituted heterocyclylC_{1-6}alkyl or $\mathbf{R^9}$ and $\mathbf{R^{10}}$ taken together can form an optionally substituted ring of 3-9 atoms or $\mathbf{R^9}$ and $\mathbf{R^{10}}$ taken together with the carbon atom to which they are attached form a carbonyl group;

$\mathbf{R^{11}}$ is selected from: hydrogen, optionally substituted C_{1-6}alkyl, or $N(\mathbf{R^9R^{10}})$;

$\mathbf{R^{12}}$ is selected from: hydrogen, hydroxy, $\mathbf{R^{17}R^{18}}N(CH_2)_{cc}$-, $\mathbf{R^{17}R^{18}}NC(O)(CH_2)_{cc}$-, optionally substituted C_{1-6}alkyl- $C(O)N(\mathbf{R^9})(CH_2)_{cc}$-, optionally substituted C_{1-6}alkyl-$SO_2N(\mathbf{R^9})$-, optionally substituted aryl-$SO_2N(\mathbf{R^9})$-, C_{1-3}perfluoroalkyl-$SO_2N(\mathbf{R^9})$-; optionally substituted C_{1-6}alkyl-$N(\mathbf{R^9})SO_2$-, optionally substituted aryl-$N(\mathbf{R^9})SO_2$-, C_{1-3}perfluoroalkyl-$N(\mathbf{R^9})SO_2$- optionally substituted C_{1-6}alkanoyl-$N(\mathbf{R^9})SO_2$-; optionally substituted aryl-$C(O)N(\mathbf{R^9})SO_2$-, optionally substituted C_{1-6}alkyl-$S(O_n)$ -, optionally substituted aryl-$S(O_n)$ - , C_{1-3}perfluoroalkyl-, C_{1-3}perfluoroalkoxy, optionally substituted C_{1-6}alkoxy, carboxy, halo, nitro or cyano;

$\mathbf{R^{13}}$ and $\mathbf{R^{14}}$ are independently selected from: hydrogen, hydroxy, oxo, optionally substituted C_{1-6}alkyl, optionally substituted C_{1-6}alkanoyl, optionally substituted C_{2-6}alkenyl, cyano, nitro, C_{1-3}perfluoroalkyl-, C_{1-3}perfluoroalkoxy, optionally substituted aryl, optionally substituted arylC_{1-6}alkyl, $\mathbf{R^9}O(CH_2)_s$-, $\mathbf{R^9}(O)O(CH_2)_s$-, $\mathbf{R^9}OC(O)(CH_2)_s$-, $\mathbf{R^{16}}S(O_n)(CH_2)_s$-, $\mathbf{R^9R^{10}}NC(O)(CH_2)_s$- or halo;

$\mathbf{R^{15}}$ is selected from: hydrogen, optionally substituted C_{1-6}alkyl, $\mathbf{R^{19}}OC(O)$-, $\mathbf{R^9R^{10}}NC(O)$-, $\mathbf{R^9}C(O)$-, $\mathbf{R^9}S(O_n)$-;

$\mathbf{R^{16}}$ is selected from: hydrogen, C_{1-6}alkyl, C_{1-3}perfluoroalkyl or optionally-substituted aryl;

$\mathbf{R^{17}}$ is independently selected from: hydrogen, hydroxy, cyano or optionally substituted C_{1-6}alkyl;

$\mathbf{R^{18}}$ is a group of formula $\mathbf{R^{18a}}$-$C(\mathbf{R^9R^{10}})_{0-1}$- wherein $\mathbf{R^{18a}}$ is selected from: $\mathbf{R^{19}}OC(O)$-, $\mathbf{R^9R^{10}}NC(O)$-, $\mathbf{R^9R^{10}}N$-, $\mathbf{R^9}C(O)$-, $\mathbf{R^9}C(O)N(\mathbf{R^{10}})$-, $\mathbf{R^9R^{10}}NC(O)$-, $\mathbf{R^9R^{10}}NC(O)N(\mathbf{R^{10}})$-, $\mathbf{R^9}SO_2N(\mathbf{R^{10}})$-, $\mathbf{R^9R^{10}}NSO_2N(\mathbf{R^{10}})$-,

$R^9C(O)O$-, $R^9OC(O)$-, $R^9R^{10}NC(O)O$-, R^9O-, $R^9S(O_n)$-, $R^9R^{10}NS(O_n)$ -, hydrogen ,optionally substituted C_{1-6}alkyl, optionally substituted heterocyclyl;

or R^{17} and R^{18} when taken together form an optionally substituted carbocyclic ring of 3-7 atoms or optionally substituted heterocyclyl;

R^{19} is selected from: hydrogen, optionally substituted C_{1-6}alky, optionally substituted aryl, optionally substituted arylC_{1-6}alkyl, optionally substituted C_{3-7}cycloalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclylC_{1-6}alkyl;

R^{21} and R^{22} are independently selected from hydrogen, optionally substituted C_{1-6}alkyl, optionally substituted C_{3-7}cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylC_{1-6}alkyl, optionally substituted C_{3-6}alkenyl, optionally substituted C_{3-6}alkynyl, -$(C_{1-5}alkyl)_{aa}$-$S(O_n)$-$(C_{1-5}alkyl)_{bb}$-; $R^9R^{10}NC_{2-6}$alkyl, R^9OC_{2-6}alkyl or $R^9R^{10}NC(O)C_{2-6}$alkyl, with the proviso that R^9 and R^{10} independently or taken together are not optionally substituted aryl or optionally substituted arylC_{1-6}alkyl; or

R^{21} and R^{22} taken together form an optionally substituted non-aromatic heterocyclic ring;

A is selected from a direct bond, optionally substituted C_{1-5}alkylene, carbonyl or -$C(O)$-$C(R^dR^d)$-, wherein R^d is independently selected from a direct bond hydrogen and C_{1-2}alkyl;

B is C_{1-6}alkylene, C_{3-6}alkenylene ,-$(C_{1-5}alkyl)_{aa}$-O-$(C_{1-5}alkyl)_{bb}$-, -$(C_{1-5}alkyl)_{aa}$-C(O)-$(C_{1-5}alkyl)_{bb}$-, -$(CH_2)_{s1}$-C(O)N(R^9)-, or the group

forms an optionally substituted saturated C_{4-7}heterocyclic ring,

wherein **aa** and **bb** are independently 0 or 1 and wherein the combined length of $(C_{1-5}alkyl)_{aa}$, $(C_{1-5}alkyl)_{bb}$ is less than or equal to C_5alkyl and wherein C_{1-6}alkylene is optionally substituted by hydroxy.

E is –O-, -S(O$_n$), -C(O)-, -N**R**^{15}- or -C(**R**^{9}**R**^{10})$_q$;

F is -**E**(CH$_2$)$_r$-;

G is selected from: hydrogen, halo, N, O, S(O$_n$), C(O), C(**R**^{9}**R**^{10})$_t$, optionally substituted C$_{2-6}$alkenylene, optionally substituted C$_{2-6}$alkynylene or a direct bond to **R**^{18},

J is a group of the formula: -(CH$_2$)$_s$-**L**-(CH$_2$)$_s$- wherein when **s** is greater than 0, the alkylene group is optionally substituted,

or the group  together forms an optionally substituted heterocyclic ring containing 4-7 carbons atoms;

K is selected from: a direct bond, -(CH$_2$)$_{s1}$-, -(CH$_2$)$_{s1}$-O-(CH$_2$)$_{s2}$-, -(CH$_2$)$_{s1}$C(O)-(CH$_2$)$_{s2}$- , -(CH$_2$)$_{s1}$S(O$_n$)-(CH$_2$)$_{s2}$-, -(CH$_2$)$_{s1}$N(**R**^{18})-(CH$_2$)$_{s2}$-, -(CH$_2$)$_{s1}$-C(O)N(**R**^{9})-(CH$_2$)$_{s2}$-, -(CH$_2$)$_{s1}$-N(**R**^{9})C(O)-(CH$_2$)$_{s2}$-, -(CH$_2$)$_{s1}$-N(**R**^{9})C(O)N(**R**^{9})-(CH$_2$)$_{s2}$-, -(CH$_2$)$_{s1}$-OC(O)-(CH$_2$)$_{s2}$-, -(CH$_2$)$_{s1}$-C(O)O-(CH$_2$)$_{s2}$-, -(CH$_2$)$_{s1}$-N(**R**^{9})C(O)O-(CH$_2$)$_{s2}$-, -(CH$_2$)$_{s1}$-OC(O)N(**R**^{9})-(CH$_2$)$_{s2}$-, -(CH$_2$)$_{s1}$-OS(O$_n$)-(CH$_2$)$_{s2}$-, or -(CH$_2$)$_{s1}$-S(O$_n$)-O-(CH$_2$)$_{s2}$--(CH$_2$)$_{s1}$-S(O)$_2$N(**R**^{9})-(CH$_2$)$_{s2}$-, -(CH$_2$)$_{s1}$-N(**R**^{9})S(O)$_2$-(CH$_2$)$_{s2}$-; wherein the -(CH$_2$)$_{s1}$- and -(CH$_2$)$_{s2}$- groups are independently optionally substituted by hydroxy or C$_{1-4}$alkyl;

L is selected from optionally substituted aryl or optionally substituted heterocyclyl;

M is –(CH$_2$)-O--;

n is an integer from 0 to 2;

p is an integer from 0 to 4;

q is an integer from 0 to 4;

r is an integer from 0 to 4;

s is an integer from 0 to 4;

s1 and **s2** are independently selected from an integer from 0 to 4, and **s1**+**s2** is less than or equal to 4;

t is an integer from 0 to 4;

aa and **bb** are independently 0 or 1; and

cc is an integer between 0 to 2;

with the proviso that

(i) when **G** is hydrogen or halo, then $\mathbf{R^{17}}$ and $\mathbf{R^{18}}$ are both absent;

(ii) when **G** is O, $S(O_n)$, C(O) or $C(\mathbf{R^{11}R^{12}})_t$ then **G** is substituted by a single group independently selected from the definition of $\mathbf{R^{17}}$ or $\mathbf{R^{18}}$ and when G is a direct bond to $\mathbf{R^{18}}$ then **G** is substituted by a single group selected from $\mathbf{R^{18}}$;

(iii) when $\mathbf{R^3}$ is a group of Formula (IIb), **B** is a group of Formula (IV), $\mathbf{R^8}$ is selected from group (i) or (ii) above, $\mathbf{R^{11}}$ is a group of the formula $N(\mathbf{R^{10}R^{11}})$ and $\mathbf{R^1}$, $\mathbf{R^2}$ and $\mathbf{R^5}$ are as defined above then $\mathbf{R^4}$ cannot be hydrogen;

(iv) $\mathbf{R^3}$ cannot be unsubstituted pyridyl or unsubstituted pyrimidinyl; and

(v) when $\mathbf{R^3}$ is pyrazolyl substituted by phenyl or pyrazolyl substituted by phenyl and acetyl, $\mathbf{R^5}$-**M** is hydroxyl or acetyloxy, $\mathbf{R^2}$ is unsubstituted phenyl, then $\mathbf{R^1}$ cannot be hydrogen or acetyl;

or a salt, or in-vivo hydrolyzable ester thereof.

19. (New) The compound of Claim 18, wherein $\mathbf{R^1}$ is hydrogen.

20. (New) The compound of Claim 18, wherein $\mathbf{R^3}$ is selected from a group of Formula (IIa) or Formula (IIb).

21. (New) The compound of Claim 20, wherein **B** is optionally substituted C_{1-6}alkylene.

22. (New) The compound of Claim 18, wherein $\mathbf{R^3}$ is selected from a group of Formula (IIc) or Formula (IId).

23. (New) The compound of Claim 22 wherein the group  together forms an optionally substituted heterocyclic ring containing 4-7 carbons atoms.

24. (New) The compound according to Claim 23 wherein **K** is selected from:
$-(CH_2)_s-$, $-(CH_2)_s-O-(CH_2)_s-$, $-(CH_2)_s-C(O)-(CH_2)_s-$, $-(CH_2)_s-N(\mathbf{R^{18}})-(CH_2)_s-$,
$-(CH_2)_s-C(O)N(\mathbf{R^{18}})-(CH_2)_s-$, $-(CH_2)_s-N(\mathbf{R^{18}})C(O)-(CH_2)_s-$,
$-(CH_2)_s-S(O)_2N(\mathbf{R^{18}})-(CH_2)_s-$, or $-(CH_2)_s-NHS(O)_2-(CH_2)_s-$.

25. (New) The compound of Claim 20 wherein $\mathbf{R^8}$ is selected from:

(i) hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, haloC_{1-6}alkyl, hydroxy, cyano, C_{1-6}alkyl$S(O_\mathbf{n})$-, -O-$\mathbf{R^b}$, C_{1-4}alkoxyC_{1-4}alkyl, -C(O)-$\mathbf{R^b}$, C(O)O-$\mathbf{R^b}$, -NH-C(O)-$\mathbf{R^b}$, N,N-di-C_{1-4}alkylamino, $-S(O_\mathbf{n})N\mathbf{R^b}\mathbf{R^c}$
where $\mathbf{R^b}$ and $\mathbf{R^c}$ are independently selected from hydrogen and C_{1-6}alkyl, and **n** is 0, 1 or 2;

(ii) -(**Q**)-aryl, optionally substituted by up to 3 groups selected from $\mathbf{R^{12}}$, $\mathbf{R^{13}}$ and $\mathbf{R^{14}}$;

(iii) C_{4-7}heterocyclyl, optionally substituted by up to 3 groups selected from $\mathbf{R^{12}}$, $\mathbf{R^{13}}$ and $\mathbf{R^{14}}$, or

(iv) C_{3-7}carbocyclyl, optionally substituted by up to 3 groups selected from $\mathbf{R^{12}}$, $\mathbf{R^{13}}$ and $\mathbf{R^{14}}$.

26. (New) The compound of Claim 18 wherein $\mathbf{R^5}$ is a group of Formula (III) wherein the group of Formula (III) is selected from any one of **III-a** to **III-l**;


III-a


III-b


III-c


III-d


III-e


III-f


III-g


III-h


III-i


III-j


III-k


III-l

wherein:

het represents an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S;

$\mathbf{R^{23}}$ and $\mathbf{R^{23a}}$ are independently selected from hydrogen, fluoro or optionally substituted $C_{1\text{-}8}$alkyl; or $\mathbf{R^{23}}$ and $\mathbf{R^{23a}}$ together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring

$\mathbf{R^{24}}$ is selected from hydrogen, optionally substituted $C_{1\text{-}8}$alkyl, optionally substituted aryl, -$\mathbf{R^d}$-Ar, where $\mathbf{R^d}$ represents $C_{1\text{-}8}$alkylene and Ar represents optionally substituted aryl, and optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S;

$\mathbf{R^{25}}$ is selected from hydrogen; optionally substituted $C_{1\text{-}8}$alkyl and optionally substituted aryl;

or where the group of Formula (III) represents a group of Formula **III-a** , **III-b** or **III-i**, then the group $NR^{24}(\text{-}R^{25})$ represents an optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S;

or where the group of Formula (III) represents structure **III-e**, R^{24} and R^{25} together with the carbon to which they are attached represents an optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S.

27. (New) The compound of Claim 18 wherein the optional substituents on R^2 are selected from cyano, NR^eR^f, optionally substituted $C_{1\text{-}8}$alkyl, optionally substituted $C_{1\text{-}8}$alkoxy or halo wherein R^e and R^f are independently selected from hydrogen, $C_{1\text{-}6}$alkyl or aryl.

28. (New) The compound of Claim 18 selected from:

2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[2-pyrid-4-ylethyl]-(2S)-propylamine;

2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[2-pyrid-4-ylbutyl]-(2S)-propylamine;

2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[4-(4-methoxyphenyl)butyl]-(2S)-propylamine;

2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[2-(43-trifluoromethylphenyl)ethyl]-(2S)-propylamine;

2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[2-(4-fluorophenyl)ethyl]-(2S)-propylamine;

2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[2-(3-methoxyphenyl)ethyl]-(2S)-propylamine;

2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[2-(4-methoxyphenyl)ethyl]-(2S)-propylamine;

2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.1]heptan-7-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[2-(4-methylsulphonylaminophenyl)ethyl]-(2S)-propylamine; and

2-[3-(2,2-dimethyl-3-oxo-3-{azabicyclo[2.2.2]oct-2-yl}propoxy)-5-(3,5-dimethylphenyl)-1*H*-pyrazol-4-yl]-*N*-[2-(1,3-benzodioxol-5-yl)ethyl]-(2S)-propylamine;

or a salt, or in-vivo hydrolyzable ester thereof.

29. (New) A pharmaceutical formulation comprising a compound, or salt, or in-vivo hydrolyzable ester thereof, according to Claim 18 and a pharmaceutically acceptable diluent or carrier.